JP2023522889A - 脂質結合タンパク質ベースの複合体を使用した、急性病態を治療するための方法 - Google Patents

脂質結合タンパク質ベースの複合体を使用した、急性病態を治療するための方法 Download PDF

Info

Publication number
JP2023522889A
JP2023522889A JP2022562954A JP2022562954A JP2023522889A JP 2023522889 A JP2023522889 A JP 2023522889A JP 2022562954 A JP2022562954 A JP 2022562954A JP 2022562954 A JP2022562954 A JP 2022562954A JP 2023522889 A JP2023522889 A JP 2023522889A
Authority
JP
Japan
Prior art keywords
binding protein
lipid binding
lipid
based complex
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022562954A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522889A5 (https=
JPWO2021209823A5 (https=
Inventor
ツピン，シリル
ペイロッテス，コンスタンス
バーバラス，ロナルド
Original Assignee
アビオニクス ファーマ エスエー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アビオニクス ファーマ エスエー filed Critical アビオニクス ファーマ エスエー
Publication of JP2023522889A publication Critical patent/JP2023522889A/ja
Publication of JP2023522889A5 publication Critical patent/JP2023522889A5/ja
Publication of JPWO2021209823A5 publication Critical patent/JPWO2021209823A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2022562954A 2020-04-16 2021-04-15 脂質結合タンパク質ベースの複合体を使用した、急性病態を治療するための方法 Pending JP2023522889A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063011055P 2020-04-16 2020-04-16
US63/011,055 2020-04-16
US202063092070P 2020-10-15 2020-10-15
US63/092,070 2020-10-15
US202063121640P 2020-12-04 2020-12-04
US63/121,640 2020-12-04
PCT/IB2021/000283 WO2021209823A1 (en) 2020-04-16 2021-04-15 Methods for treating acute conditions using lipid binding protein- based complexes

Publications (3)

Publication Number Publication Date
JP2023522889A true JP2023522889A (ja) 2023-06-01
JP2023522889A5 JP2023522889A5 (https=) 2024-04-25
JPWO2021209823A5 JPWO2021209823A5 (https=) 2024-04-25

Family

ID=76197484

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022562954A Pending JP2023522889A (ja) 2020-04-16 2021-04-15 脂質結合タンパク質ベースの複合体を使用した、急性病態を治療するための方法

Country Status (10)

Country Link
US (1) US20240033322A1 (https=)
EP (1) EP4135747A1 (https=)
JP (1) JP2023522889A (https=)
KR (1) KR20230004605A (https=)
CN (1) CN115427064A (https=)
AU (1) AU2021256086A1 (https=)
CA (1) CA3177243A1 (https=)
IL (1) IL297336A (https=)
MX (1) MX2022012969A (https=)
WO (1) WO2021209823A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024514154A (ja) * 2021-04-15 2024-03-28 アビオニクス ファーマ エスエー 臓器保存溶液における脂質結合タンパク質ベースの複合体の使用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297046A (en) 2020-04-16 2022-12-01 Abionyx Pharma Sa Treatment of kidney disease using cer-001
CA3247588A1 (en) * 2022-04-06 2023-10-12 Abionyx Pharma Sa METHODS FOR TREATING LEUKOCYTOSIS, ENDOTHELIAL DYSFUNCTION AND CARDITIS USING LIPID-BINDING PROTEIN COMPLEXES
JP2025519606A (ja) * 2022-06-10 2025-06-26 アビオニクス ファーマ エスエー 脂質結合タンパク質に基づく複合体を使用して急性状態を処置するための方法
WO2023237927A2 (en) * 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
WO2024150064A1 (en) * 2023-01-13 2024-07-18 Abionyx Pharma Sa Lipid binding protein molecule therapy
CN116893215A (zh) * 2023-03-17 2023-10-17 安徽省立医院(中国科学技术大学附属第一医院) 一种用于监测car-t治疗之后crs进程的临床标志物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022548077A (ja) * 2019-09-12 2022-11-16 エタブリセマン・フランセ・デュ・サン 移植片対宿主病の予防におけるｈｄｌの使用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128318A (en) 1987-05-20 1992-07-07 The Rogosin Institute Reconstituted HDL particles and uses thereof
GB8712540D0 (en) 1987-05-28 1987-07-01 Ucb Sa Expression of human proapolipoprotein a-i
US5220043A (en) 1991-03-21 1993-06-15 Ohio University Synthesis of D-erythro-sphingomyelins
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
JP3754072B2 (ja) 1994-03-22 2006-03-08 リサーチ・コーポレーション・テクノロジーズ・インコーポレーテッド 摂食抑制ペプチド
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) * 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
AU2001257173B2 (en) 2000-04-21 2005-09-22 Amgen Inc. Apo-ai/aii peptide derivatives
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7148197B2 (en) 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
EP2343317A1 (en) 2000-11-10 2011-07-13 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
US7217785B2 (en) 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
CA2457840C (en) 2001-08-20 2011-10-11 Zlb Bioplasma Ag Hdl for the treatment of stroke and other ischemic conditions
US7223726B2 (en) 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
AU2003239489A1 (en) 2002-05-17 2003-12-02 Esperion Therapeutics, Inc. Method of treating dyslipidemic disorders
EP1545576A2 (en) * 2002-07-30 2005-06-29 Esperion Therapeutics Inc. Methods of using non-human animal apoliprotein a-i protein
EP2314285B2 (en) 2003-02-14 2019-09-18 Children's Hospital & Research Center at Oakland Lipophilic drug delivery vehicle and methods of use thereof
CN101076541A (zh) 2004-07-16 2007-11-21 塔夫茨大学信托人 载脂蛋白a1模拟物及其用途
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
AU2006282722A1 (en) 2005-08-26 2007-03-01 Cerenis Therapeutics Holdings S.A. Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria
US8541236B2 (en) 2006-12-08 2013-09-24 University Of Washington Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
WO2008104890A2 (en) 2007-02-28 2008-09-04 Cerenis Therapeutics Holding Sa Compositions and methods for producing apolipoprotein
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
EA201070517A1 (ru) 2007-10-23 2010-12-30 Дзе Кливленд Клиник Фаундейшн Устойчивый к окислителям аполипопротеин а-1 и пептиды-миметики
LT2939683T (lt) 2009-02-16 2017-03-27 Cerenis Therapeutics Holding Sa Apolipoproteino a-i mimetikai
US20130137628A1 (en) 2010-05-11 2013-05-30 Esperion Therapeutics, Inc. Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
EP2673296B1 (en) * 2011-02-07 2018-10-24 Cerenis Therapeutics Holding SA Lipoprotein complexes and manufacturing and uses thereof
JP6438417B2 (ja) 2013-03-15 2018-12-12 セレニス セラピューティクス ホールディング エスアー スフィンゴミエリンおよびジヒドロスフィンゴミエリンの合成のための方法
US9708354B2 (en) 2013-03-15 2017-07-18 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
EP2853259A1 (en) * 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
WO2015173633A2 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
WO2018029505A1 (en) * 2016-08-11 2018-02-15 Cerenis Therapeutics Holding Sa Cer-001 therapy for treating familial primary hypoalphalipoproteinemia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022548077A (ja) * 2019-09-12 2022-11-16 エタブリセマン・フランセ・デュ・サン 移植片対宿主病の予防におけるｈｄｌの使用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
MCDONALD M. C. ET AL., SHOCK, vol. 20, no. 6, JPN6025007484, 2003, pages 551 - 557, ISSN: 0005737819 *
MORIN E. E. ET AL., FRONTIERS IN PHARMACOLOGY, vol. Vol.6 Article 244, JPN6025007481, 2015, ISSN: 0005737816 *
PAJKRT D. ET AL., J. EXP. MED., vol. 184, JPN6025007483, 1996, pages 1601 - 1608, ISSN: 0005737818 *
TANAKA S. ET AL., ANESTHESIOLOGY, vol. 132, no. 4, JPN6025007485, 20 February 2020 (2020-02-20), pages 825 - 838, ISSN: 0005540729 *
TARDY C. ET AL., ATHEROSCLEROSIS, vol. 232, JPN6025007482, 2014, pages 110 - 118, ISSN: 0005737817 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024514154A (ja) * 2021-04-15 2024-03-28 アビオニクス ファーマ エスエー 臓器保存溶液における脂質結合タンパク質ベースの複合体の使用

Also Published As

Publication number Publication date
WO2021209823A1 (en) 2021-10-21
AU2021256086A1 (en) 2022-12-15
KR20230004605A (ko) 2023-01-06
CA3177243A1 (en) 2021-10-21
IL297336A (en) 2022-12-01
MX2022012969A (es) 2022-11-09
US20240033322A1 (en) 2024-02-01
CN115427064A (zh) 2022-12-02
EP4135747A1 (en) 2023-02-22

Similar Documents

Publication Publication Date Title
JP2023522889A (ja) 脂質結合タンパク質ベースの複合体を使用した、急性病態を治療するための方法
JP2006508045A (ja) ヒト以外の動物のアポリポプロテインａ−ｉタンパク質の使用方法
ES2984286T3 (es) Apómeros
JP2014028839A (ja) 顆粒球マクロファージコロニー刺激因子を投与することによる肺の宿主防御の増強
US20250134949A1 (en) Prominin-1 peptide for treating lung injury
JP6158097B2 (ja) 炎症を抑制するためのペプチド
WO2013049321A1 (en) Use of hemopexin to sequester hemoglobin
JP2026504047A (ja) 脂質結合タンパク質分子療法
US20250255931A1 (en) Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
US20250360184A1 (en) Methods for treating acute conditions using lipid binding protein-based complexes
WO2025093929A1 (en) Lipid binding protein molecule therapy
JP2025518942A (ja) 脂質結合タンパク質に基づく複合体を使用して高炎症状態を処置するための方法
CN119233984A (zh) 短载脂蛋白e模拟肽及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240415

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250829

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260324